HomeCompareIPSEY vs DVY

IPSEY vs DVY: Dividend Comparison 2026

IPSEY yields 0.86% · DVY yields 3.50%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPSEY wins by $2.9K in total portfolio value· pulled ahead in Year 8
10 years
IPSEY
IPSEY
● Live price
0.86%
Share price
$46.30
Annual div
$0.40
5Y div CAGR
33.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$2,101.14
Full IPSEY calculator →
DVY
DVY
● Live price
3.50%
Share price
$150.03
Annual div
$5.25
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$437.78
Full DVY calculator →

Portfolio growth — IPSEY vs DVY

📍 IPSEY pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPSEYDVY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPSEY + DVY cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPSEY pays
DVY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPSEY
Annual income on $10K today (after 15% tax)
$73.26/yr
After 10yr DRIP, annual income (after tax)
$1,785.97/yr
DVY
Annual income on $10K today (after 15% tax)
$297.17/yr
After 10yr DRIP, annual income (after tax)
$372.11/yr
At 15% tax rate, IPSEY beats the other by $1,413.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPSEY + DVY for your $10,000?

IPSEY: 50%DVY: 50%
100% DVY50/50100% IPSEY
Portfolio after 10yr
$26.5K
Annual income
$1,269.46/yr
Blended yield
4.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on IPSEY right now

IPSEY
Analyst Ratings
2
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
14.0
Piotroski
7/9
DVY
No analyst data
Altman Z
307.5
Piotroski
1/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPSEY buys
0
DVY buys
0
No recent congressional trades found for IPSEY or DVY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPSEYDVY
Forward yield0.86%3.50%
Annual dividend / share$0.40$5.25
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.9%0%
Portfolio after 10y$28.0K$25.1K
Annual income after 10y$2,101.14$437.78
Total dividends collected$7.1K$4.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IPSEY vs DVY ($10,000, DRIP)

YearIPSEY PortfolioIPSEY Income/yrDVY PortfolioDVY Income/yrGap
1$10,815$115.41$11,050$349.62$235.00DVY
2$11,729$156.20$12,184$361.04$455.00DVY
3$12,762$211.97$13,409$372.07$647.00DVY
4$13,944$288.63$14,730$382.68$786.00DVY
5$15,314$394.64$16,154$392.89$840.00DVY
6$16,929$542.40$17,688$402.69$759.00DVY
7$18,864$750.31$19,338$412.07$474.00DVY
8← crossover$21,231$1,046.28$21,113$421.04+$118.00IPSEY
9$24,191$1,473.60$23,020$429.61+$1.2KIPSEY
10$27,985$2,101.14$25,070$437.78+$2.9KIPSEY

IPSEY vs DVY: Complete Analysis 2026

IPSEYStock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Full IPSEY Calculator →

DVYETF

The iShares Select Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full DVY Calculator →
📬

Get this IPSEY vs DVY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPSEY vs SCHDIPSEY vs JEPIIPSEY vs OIPSEY vs KOIPSEY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.